Severe steroid refractory gastritis induced by Nivolumab: A case report

作     者：Helene Hjorth Vindum JØrgen S Agnholt Anders Winther Moelby Nielsen Mette Bak Nielsen Henrik Schmidt 

作者机构：Department of OncologyAarhus University HospitalAarhus 8200Denmark Department of GastroenterologyAarhus University HospitalAarhus 8200Denmark Department of PathologyAarhus University HospitalAarhus 8200Denmark 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2020年第26卷第16期

页      面：1971-1978页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Gastritis Immune checkpoint inhibitors Nivolumab Case report Immune-related adverse events Infliximab 

摘      要：BACKGROUND Immune checkpoint inhibitors are widely used for treatment of many advanced *** gastrointestinal(GI)side effects,such as diarrhea and colitis,are common,but upper GI side effects are rarely ***,the correct treatment of upper GI adverse events has been less frequently *** SUMMARY We describe a case of a 16-year-old woman with stage IIIb malignant melanoma treated with adjuvant monotherapy using *** patient developed severe gastritis after six series of Nivolumab with weight loss,nausea,and *** was no effect of intravenous steroids,but the patient′s condition resolved after administration of *** This case report supports the same treatment for gastritis as for colitis,which is in line with current guidelines.